Gritstone bio Inc., entered into a clinical trial agreement with NCI to evaluate an autologous T-cell therapy expressing a T-cell receptor targeting mutated KRAS in combination with Gritstone’s KRAS-directed vaccine candidate, SLATE-KRAS, in a phase I study. The study will be led by Steven A. Rosenberg, chief of the surgery branch at NCI’s Center for Cancer Research.
With advances in treatment and screening for earlier detection, oncologists have improved cancer survival rates dramatically. That is excellent news, but the surging number of survivors means it is increasingly important for providers to focus more diligently on what patients need to thrive after treatment.
